Other
Biomarkers
0
Pipeline Programs↗
23
Active Trials↗
14
Companies Involved↗
Biomarkers is an early-stage landscape with 0 programs across 14 companies. The most active players are Novartis, Pfizer, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
120
clinical trials
Completed64 · 53%
Unknown status18 · 15%
Recruiting16 · 13%
Terminated10 · 8%
Withdrawn4 · 3%
Not yet recruiting3 · 3%
Other5 · 4%
Clinical Trials
Trial Activity
120 trials
Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod
Recruiting·—·Phase 4·NCT06356012·96 enrolled
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
Recruiting·—·N/A·NCT04417803·1,200 enrolled
BEGIN Novel ImagiNG Biomarkers
Recruiting·—·Phase 4·NCT05517655·44 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)